Gemcitabine: Future prospects of single-agent and combination studies

Oncologist

Volumn 2, Issue 3, 1997, Pages 127-134

  Van Moorsel, Catharina J A ^a   Peters, Godefridus J ^a   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antimetabolites; Breast cancer; Ciplatin; Deoxycytidine kinase; Gemcitabine; Non small cell lung cancer; Pancreatic cancer; Taxanes

Indexed keywords

AMINOTRANSFERASE; ANALGESIC AGENT; CARBOPLATIN; CISPLATIN; CYTARABINE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; HYDROXYUREA; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PHOSPHOTRANSFERASE; RADIOSENSITIZING AGENT; RIBONUCLEOTIDE REDUCTASE; RNA; TAXANE DERIVATIVE; TOPOTECAN; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BOLUS INJECTION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DRUG INFUSION; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; LETHARGY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0030915362     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.2-3-127     Document Type: Review

References (19)

1. Bishop JF, Matthews JP, Young GA et al. A randomized study of high-dose cytarabine in induction therapy in acute myeloid leukemia. Blood 1996;5:1710-1717.
2. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6(suppl 6):7-13.
3. Heinemann V, Hertel LW, Grindey OB et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-4031.
4. Arnér ESJ, Eriksson S. Mammalian deoxyribonudeoside kinases. Pharmac Ther 1995;67:155-186.
5. Huang P, Chubb S, Hertel LW et al. Action of 2′2,′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-6117.
6. Ruiz van Haperen VWT, Veerman G, Vermorken JB et al. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol 1993;46:762-766.
7. Ruiz van Haperen VWT, Veerman G, Vermorken JB et al. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1996;51:911-918.
8. Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem 1992;207:163-167.
9. Plunkett W, Huang P, Xu Y-Z et al. Gemcitabine; metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(suppl 11):3-10.
10. Braakhuis BJM, Ruiz van Haperen VWT, Boven E et al. Schedule dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 1995;22(suppl 11):42-46.
11. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-4422.
12. Braakhuis BJM, Van Dongen GMAS, Vermorken JB et al. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991;51:211-214.
13. Merriman RL, Hertel LW, Schultz RM et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996;14:243-247.
14. Boven E, Schipper H, Erkelens CAM et al. The influence of schedule and dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br J Cancer 1993;68:52-56.
15. Veerman G, Ruiz van Haperen VWT, Vermorken JB et al. Superior therapeutic activity of prolonged compared to bolus administration of 2′,2′-difluorodeoxycytidine (gemcitabine) in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-342.
16. O'Rourke TJ, Brown TD, Havlin K et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 1994;30A:417-419.
17. Poplin EA, Corbett T, Flaherty L et al. Difluorodeoxycytidine (dFdC)-gemcitabine: a Phase I study. Invest New Drugs 1992;10:165-170.
18. Abbruzzese JL, Grunewald R, Weeks EA et al. A Phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
19. Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics of antimetabolites. Cancer Surveys 1993;17:123-156.